Matthew Galsky Department of Hematology/Oncology, Tisch Cancer Institute Icahn School of Medicine at Mount Sinai Biography Publications Institution JoVE Articles Matthew Galsky has not added a biography. If you are Matthew Galsky and would like to personalize this page please email our Author Liaison for assistance. Publications Phase 2 Trial of the Topoisomerase II Inhibitor, Amrubicin, As Second-line Therapy in Patients with Metastatic Urothelial Carcinoma Cancer Chemotherapy and Pharmacology. Oct, 2015 | Pubmed ID: 26464352 Neoadjuvant Dasatinib for Muscle-invasive Bladder Cancer with Tissue Analysis of Biologic Activity Urologic Oncology. Sep, 2015 | Pubmed ID: 26362343 A Robust Blood Gene Expression-based Prognostic Model for Castration-resistant Prostate Cancer BMC Medicine. 2015 | Pubmed ID: 26297150 Reporting Quality of Abstracts in Phase III Clinical Trials of Systemic Therapy in Metastatic Solid Malignancies Trials. 2015 | Pubmed ID: 26253548 Concurrent Diabetes Mellitus May Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer Frontiers in Oncology. 2015 | Pubmed ID: 26125012 Neoadjuvant Chemotherapy in the Management of Muscle-invasive Bladder Cancer: Bridging the Gap Between Evidence and Practice The Urologic Clinics of North America. May, 2015 | Pubmed ID: 25882560 Comparative Effectiveness of Gemcitabine Plus Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin As Neoadjuvant Therapy for Muscle-invasive Bladder Cancer Cancer. Aug, 2015 | Pubmed ID: 25872978 The Landscape of Precision Cancer Medicine Clinical Trials in the United States Cancer Treatment Reviews. May, 2015 | Pubmed ID: 25864024 First-line Treatment of Metastatic Disease: Cisplatin-ineligible Patients Hematology/oncology Clinics of North America. Apr, 2015 | Pubmed ID: 25836938 Clinical Trial Awareness: Changes over Time and Sociodemographic Disparities Clinical Trials (London, England). Jun, 2015 | Pubmed ID: 25673636 A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer Cancer Cell. Feb, 2015 | Pubmed ID: 25670080 The Impact of Regionalization of Cystectomy on Racial Disparities in Bladder Cancer Care The Journal of Urology. Jul, 2015 | Pubmed ID: 25623748 Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease The Journal of Urology. Jul, 2015 | Pubmed ID: 25623747 Kidney Cancer: Systemic Therapy--differentiating the Achievable from the Achieved Nature Reviews. Urology. Mar, 2015 | Pubmed ID: 25600095 Elevated Circulating Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) Levels Are Associated with Neuroendocrine Differentiation in Castration Resistant Prostate Cancer The Prostate. May, 2015 | Pubmed ID: 25560638 Survival of Patients with Stage IV Lung Cancer with Diabetes Treated with Metformin American Journal of Respiratory and Critical Care Medicine. Feb, 2015 | Pubmed ID: 25522257 How I Treat Bladder Cancer in Elderly Patients Journal of Geriatric Oncology. Jan, 2015 | Pubmed ID: 25482022 Complete Response As an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma Clinical Genitourinary Cancer. Apr, 2015 | Pubmed ID: 25458370 Geographic Accessibility to Clinical Trials for Advanced Cancer in the United States JAMA Internal Medicine. Feb, 2015 | Pubmed ID: 25437434 Clinical Decision Making in Castration-resistant Prostate Cancer According to Baseline Prostate-specific Antigen: Are We Measuring Disease Burden or Disease Biology? European Urology. Feb, 2015 | Pubmed ID: 25220371 Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to Move Research Forward Urologic Oncology. Feb, 2015 | Pubmed ID: 25065704 Cytotoxic Chemotherapy in the Contemporary Management of Metastatic Castration-resistant Prostate Cancer (mCRPC) BJU International. Jul, 2015 | Pubmed ID: 25046451 A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer European Urology. Jan, 2015 | Pubmed ID: 24841777 Repurposing of Bisphosphonates for the Prevention and Therapy of Nonsmall Cell Lung and Breast Cancer Proceedings of the National Academy of Sciences of the United States of America. Dec, 2014 | Pubmed ID: 25453078 Biomarkers for Bladder Cancer Management: Present and Future American Journal of Clinical and Experimental Urology. 2014 | Pubmed ID: 25374904 Is Prostate Cancer Changing?: Evolving Patterns of Metastatic Castration-resistant Prostate Cancer Cancer. Mar, 2014 | Pubmed ID: 25302607 Use of Crowdsourcing for Cancer Clinical Trial Development Journal of the National Cancer Institute. Oct, 2014 | Pubmed ID: 25217580 Adult Cancer Clinical Trials That Fail to Complete: an Epidemic? Journal of the National Cancer Institute. Sep, 2014 | Pubmed ID: 25190726 Cisplatin Vs. Carboplatin-based Chemoradiotherapy in Patients >65 Years of Age with Stage III Non-small Cell Lung Cancer Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology. Aug, 2014 | Pubmed ID: 25150635 Rethinking Cancer Clinical Trials for the Future Future Oncology (London, England). 2014 | Pubmed ID: 25145425 Phase Ib/II Trial of Gemcitabine, Cisplatin, and Lenalidomide As First-line Therapy in Patients with Metastatic Urothelial Carcinoma The Oncologist. Sep, 2014 | Pubmed ID: 25052451 Patient Eligibility and Trial Design for the Salvage Therapy of Advanced Urothelial Carcinoma Clinical Genitourinary Cancer. Dec, 2014 | Pubmed ID: 25035282 Phase Ib Study of Dovitinib in Combination with Gemcitabine Plus Cisplatin or Gemcitabine Plus Carboplatin in Patients with Advanced Solid Tumors Cancer Chemotherapy and Pharmacology. Sep, 2014 | Pubmed ID: 25023489 New Drugs and Treatment Strategies in Prostate Cancer Clinical Advances in Hematology & Oncology : H&O. Jan, 2014 | Pubmed ID: 25000316 Mind the Gap: Efficacy Versus Effectiveness and Pivotal Prostate Cancer Clinical Trial Demographics Cancer. Oct, 2014 | Pubmed ID: 24965362 Current Approaches to the Management of Bladder Cancer in Older Patients American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting. 2014 | Pubmed ID: 24857110 Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis American Journal of Clinical Oncology. May, 2014 | Pubmed ID: 24824144 T2 Muscle-invasive Bladder Cancer Seminars in Oncology. Apr, 2014 | Pubmed ID: 24787300 A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jul, 2014 | Pubmed ID: 24727324 Targeting Vascular Endothelial Growth Factor Receptor Signaling in Renal Cancer: the Sooner the Better? European Urology. Nov, 2014 | Pubmed ID: 24631407 Safety and Efficacy of Addition of VEGFR and EGFR-family Oral Small-molecule Tyrosine Kinase Inhibitors to Cytotoxic Chemotherapy in Solid Cancers: a Systematic Review and Meta-analysis of Randomized Controlled Trials Cancer Treatment Reviews. Jun, 2014 | Pubmed ID: 24629273 Impact of Prednisone on Toxicities and Survival in Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Clinical Trials Critical Reviews in Oncology/hematology. Jun, 2014 | Pubmed ID: 24500033 Is Metastatic Prostate Cancer Changing, and How Will We Know It? It's Time for Standard Nomenclature for Nonosseous Metastases in Clinical Trials of Patients with Metastatic Castration Resistant Prostate Cancer European Urology. Aug, 2014 | Pubmed ID: 24433812 Cisplatin-ineligible and Chemotherapy-ineligible Patients Should Be the Focus of New Drug Development in Patients with Advanced Bladder Cancer Clinical Genitourinary Cancer. Apr, 2014 | Pubmed ID: 24355418 Prognostic Risk Stratification Derived from Individual Patient Level Data for Men with Advanced Penile Squamous Cell Carcinoma Receiving First-line Systemic Therapy Urologic Oncology. May, 2014 | Pubmed ID: 24332646 Adverse Event Reporting in Cancer Clinical Trial Publications Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Jan, 2014 | Pubmed ID: 24323037 Radiographic Progression by Prostate Cancer Working Group (PCWG)-2 Criteria As an Intermediate Endpoint for Drug Development in Metastatic Castration-resistant Prostate Cancer BJU International. Dec, 2014 | Pubmed ID: 24298897 Six-month Progression-free Survival As the Primary Endpoint to Evaluate the Activity of New Agents As Second-line Therapy for Advanced Urothelial Carcinoma Clinical Genitourinary Cancer. Apr, 2014 | Pubmed ID: 24220220 A Nomogram Including Baseline Prognostic Factors to Estimate the Activity of Second-line Therapy for Advanced Urothelial Carcinoma BJU International. May, 2014 | Pubmed ID: 24219029 Posttreatment Prognostic Nomogram for Patients with Metastatic Urothelial Cancer Completing First-line Cisplatin-based Chemotherapy Urologic Oncology. Jan, 2014 | Pubmed ID: 24055428 Metastatic Renal Cancer: Better Never Than Late European Urology. Jun, 2014 | Pubmed ID: 23954087 Pulmonary Complications with the Use of MTOR Inhibitors in Targeted Cancer Therapy: a Systematic Review and Meta-analysis Targeted Oncology. Sep, 2014 | Pubmed ID: 23852656 Toxicities Following Treatment with Bisphosphonates and Receptor Activator of Nuclear Factor-κB Ligand Inhibitors in Patients with Advanced Prostate Cancer European Urology. Feb, 2014 | Pubmed ID: 23706567 Association of the Charlson Comorbidity Index and Hypertension with Survival in Men with Metastatic Castration-resistant Prostate Cancer Urologic Oncology. Jan, 2014 | Pubmed ID: 23685020 Metabolic Complications with the Use of MTOR Inhibitors for Cancer Therapy Cancer Treatment Reviews. Feb, 2014 | Pubmed ID: 23684373 Cisplatin-based Combination Chemotherapy in Septuagenarians with Metastatic Urothelial Cancer Urologic Oncology. Jan, 2014 | Pubmed ID: 23428534 Risk of Hematologic Toxicities in Patients with Solid Tumors Treated with Everolimus: a Systematic Review and Meta-analysis Critical Reviews in Oncology/hematology. Oct, 2013 | Pubmed ID: 23830806 Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel-based Chemotherapy Clinical Genitourinary Cancer. Dec, 2013 | Pubmed ID: 23816526 Impact of Response to Prior Chemotherapy in Patients with Advanced Urothelial Carcinoma Receiving Second-line Therapy: Implications for Trial Design Clinical Genitourinary Cancer. Dec, 2013 | Pubmed ID: 23800847 Tumour Angiogenesis: an Elusive Target in Castration-resistant Prostate Cancer The Lancet. Oncology. Jul, 2013 | Pubmed ID: 23742876 Nomogram for Predicting Survival in Patients with Unresectable And/or Metastatic Urothelial Cancer Who Are Treated with Cisplatin-based Chemotherapy Cancer. Aug, 2013 | Pubmed ID: 23720216 Relationship Between 6- and 9-month Progression-free Survival and Overall Survival in Patients with Metastatic Urothelial Cancer Treated with First-line Cisplatin-based Chemotherapy Cancer. Aug, 2013 | Pubmed ID: 23720197 A New Approach to Second-line Therapy for Urothelial Cancer? The Lancet. Oncology. Jul, 2013 | Pubmed ID: 23706984 The Impact of Gender on Outcomes in Patients with Metastatic Urothelial Carcinoma Clinical Genitourinary Cancer. Sep, 2013 | Pubmed ID: 23673281 Intermittent Androgen-deprivation Therapy in Prostate Cancer: a Critical Review Focused on Phase 3 Trials European Urology. Nov, 2013 | Pubmed ID: 23628492 Advances in the Management of Muscle-invasive Bladder Cancer Through Risk Prediction, Risk Communication, and Novel Treatment Approaches Clinical Advances in Hematology & Oncology : H&O. Feb, 2013 | Pubmed ID: 23598909 Metabolic and Toxicological Considerations of Newly Approved Prostate Cancer Drugs Expert Opinion on Drug Metabolism & Toxicology. Jul, 2013 | Pubmed ID: 23581700 Critical Analysis of Contemporary Clinical Research in Muscle-invasive and Metastatic Urothelial Cancer: a Report from the Bladder Cancer Advocacy Network Clinical Trials Working Group Cancer. Jun, 2013 | Pubmed ID: 23456777 Risk of Hematologic Toxicities in Cancer Patients Treated with Sunitinib: a Systematic Review and Meta-analysis Cancer Treatment Reviews. Nov, 2013 | Pubmed ID: 23455076 Pooled Analysis of Phase II Trials Evaluating Weekly or Conventional Cisplatin As First-line Therapy for Advanced Urothelial Carcinoma Clinical Genitourinary Cancer. Sep, 2013 | Pubmed ID: 23332638 Venous Thromboembolic Events with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: a Systematic Review and Meta-analysis of Randomized Clinical Trials Critical Reviews in Oncology/hematology. Jul, 2013 | Pubmed ID: 23317774 A Prognostic Model for Metastatic Renal-cell Carcinoma The Lancet. Oncology. Feb, 2013 | Pubmed ID: 23312462 Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy in the United States: a SEER Analysis World Journal of Urology. Dec, 2013 | Pubmed ID: 23223962 Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: a Retrospective Analysis of Pooled, Prospective Phase 2 Trials European Urology. Apr, 2013 | Pubmed ID: 23206856 ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma-neoadjuvant and Adjuvant Settings European Urology. Jan, 2013 | Pubmed ID: 22917984 Trends and Variations in Utilization of Nephron-sparing Procedures for Stage I Kidney Cancer in the United States World Journal of Urology. Oct, 2013 | Pubmed ID: 22622394 Efficacy of Docetaxel-based Chemotherapy Following Ketoconazole in Metastatic Castration-resistant Prostate Cancer: Implications for Prior Therapy in Clinical Trials Urologic Oncology. Nov, 2013 | Pubmed ID: 22552048 The Follicle-stimulating Hormone Receptor: a Novel Target in Genitourinary Malignancies Urologic Oncology. Nov, 2013 | Pubmed ID: 22513137 Summary of the 6th Annual Bladder Cancer Think Tank: New Directions in Urologic Research Urologic Oncology. Oct, 2013 | Pubmed ID: 22300756 New Developments in Urothelial Cancer American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting. 2012 | Pubmed ID: 24451754 Emerging Personalized Approaches for the Management of Advanced Urothelial Carcinoma Expert Review of Anticancer Therapy. Dec, 2012 | Pubmed ID: 23253220 Gemcitabine Cisplatine Et Sunitinib Métastatique Carcinome Urothélial Et Comme Traitement Préopératoire Pour Cancer De La Vessie Envahissement Musculaire Clinical Genitourinary Cancer. Dec, 2012 | Pubmed ID: 23228446 Risk of Venous Thromboembolism in Patients with Cancer Treated with Cisplatin: a Systematic Review and Meta-analysis Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Dec, 2012 | Pubmed ID: 23150697 Arterial Thromboembolism in Cancer Patients Treated with Cisplatin: a Systematic Review and Meta-analysis Journal of the National Cancer Institute. Dec, 2012 | Pubmed ID: 23093559 A Whole-blood RNA Transcript-based Prognostic Model in Men with Castration-resistant Prostate Cancer: a Prospective Study The Lancet. Oncology. Nov, 2012 | Pubmed ID: 23059047 Neutropenia As a Potential Pharmacodynamic Marker for Docetaxel-based Chemotherapy in Men with Metastatic Castration-resistant Prostate Cancer Clinical Genitourinary Cancer. Dec, 2012 | Pubmed ID: 23000202 Targeting the Androgen Receptor Signalling Axis in Castration-resistant Prostate Cancer (CRPC) BJU International. Dec, 2012 | Pubmed ID: 22985411 Editorial Comment The Journal of Urology. Oct, 2012 | Pubmed ID: 22901587 Antiangiogenic Treatment in Metastatic Urothelial Cancer The Lancet. Oncology. Aug, 2012 | Pubmed ID: 22819171 Phase II Trial of Concurrent Sunitinib and Image-guided Radiotherapy for Oligometastases PloS One. 2012 | Pubmed ID: 22761653 Prevalence and Characteristics of Patients with Metastatic Cancer Who Receive No Anticancer Therapy Cancer. Dec, 2012 | Pubmed ID: 22707387 Is Adjunctive Systemic Chemotherapy After Cystectomy for T2N+ Disease of Therapeutic Benefit? The Journal of Urology. Aug, 2012 | Pubmed ID: 22704119 Un Examen Systématique De La Chimiothérapie Néoadjuvante Et Adjuvant Pour Le Cancer De La Vessie Envahissement Musculaire European Urology. Sep, 2012 | Pubmed ID: 22677572 Targeting the FOXO1/KLF6 Axis Regulates EGFR Signaling and Treatment Response The Journal of Clinical Investigation. Jul, 2012 | Pubmed ID: 22653055 Trends in the Use of Cytoreductive Nephrectomy in the United States Clinical Genitourinary Cancer. Sep, 2012 | Pubmed ID: 22651971 Treatment-related Mortality with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients with Advanced Solid Tumors: a Meta-analysis Cancer Treatment Reviews. Nov, 2012 | Pubmed ID: 22651902 The Emerging Role of Circulating Tumor Cell Detection in Genitourinary Cancer The Journal of Urology. Jul, 2012 | Pubmed ID: 22578722 Clinical Development of Novel Therapeutics for Castration-resistant Prostate Cancer: Historic Challenges and Recent Successes CA: a Cancer Journal for Clinicians. Sep-Oct, 2012 | Pubmed ID: 22535487 Ability of C-reactive Protein to Complement Multiple Prognostic Classifiers in Men with Metastatic Castration Resistant Prostate Cancer Receiving Docetaxel-based Chemotherapy BJU International. Dec, 2012 | Pubmed ID: 22520631 Novel Molecular Targets for the Therapy of Urothelial Carcinoma Expert Opinion on Therapeutic Targets. May, 2012 | Pubmed ID: 22510032 Overcoming Castration Resistance in Prostate Cancer Current Opinion in Urology. May, 2012 | Pubmed ID: 22472508 Objective Measures of Physical Functional Capacity Warrant Exploration to Complement or Replace the Subjective Physician Estimated Performance Status American Journal of Clinical Oncology. Apr, 2012 | Pubmed ID: 22433994 Editorial Comment The Journal of Urology. May, 2012 | Pubmed ID: 22425108 Association of Rash with Outcomes in a Randomized Phase II Trial Evaluating Cetuximab in Combination with Mitoxantrone Plus Prednisone After Docetaxel for Metastatic Castration-resistant Prostate Cancer Clinical Genitourinary Cancer. Mar, 2012 | Pubmed ID: 22340631 Phase 2 Study of Neoadjuvant Docetaxel Plus Bevacizumab in Patients with High-risk Localized Prostate Cancer: a Prostate Cancer Clinical Trials Consortium Trial Cancer. Oct, 2012 | Pubmed ID: 22282219 Impact of the CKD-EPI Equation for Estimating Renal Function on Eligibility for Cisplatin-based Chemotherapy in Patients with Urothelial Cancer Clinical Genitourinary Cancer. Mar, 2012 | Pubmed ID: 22130294 Target-specific, Histology-independent, Randomized Discontinuation Study of Lapatinib in Patients with HER2-amplified Solid Tumors Investigational New Drugs. Apr, 2012 | Pubmed ID: 20857170 Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients with Castration-resistant Prostate Cancer Urology. Sep, 2011 | Pubmed ID: 21762967 Role of American Society of Clinical Oncology in Low- and Middle-income Countries Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Aug, 2011 | Pubmed ID: 21709190 Retrospective Analysis of Satraplatin in Patients with Metastatic Urothelial Cancer Refractory to Standard Platinum-based Chemotherapy Clinical Genitourinary Cancer. Sep, 2011 | Pubmed ID: 21700509 Clinical Development of Cabazitaxel for the Treatment of Castration-resistant Prostate Cancer Clinical Medicine Insights. Oncology. 2011 | Pubmed ID: 21695098 Treatment of Patients with Metastatic Urothelial Cancer "unfit" for Cisplatin-based Chemotherapy Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Jun, 2011 | Pubmed ID: 21555688 A Consensus Definition of Patients with Metastatic Urothelial Carcinoma Who Are Unfit for Cisplatin-based Chemotherapy The Lancet. Oncology. Mar, 2011 | Pubmed ID: 21376284 Randomized Phase II Trial of Single-agent Amrubicin or Topotecan As Second-line Treatment in Patients with Small-cell Lung Cancer Sensitive to First-line Platinum-based Chemotherapy Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Jan, 2011 | Pubmed ID: 21135284 Azacitidine Favorably Modulates PSA Kinetics Correlating with Plasma DNA LINE-1 Hypomethylation in Men with Chemonaïve Castration-resistant Prostate Cancer Urologic Oncology. Nov-Dec, 2011 | Pubmed ID: 19959380 Bladder Cancer: Current Management and Opportunities for a Personalized Approach The Mount Sinai Journal of Medicine, New York. Nov-Dec, 2010 | Pubmed ID: 21105122 Cabazitaxel Nature Reviews. Drug Discovery. Sep, 2010 | Pubmed ID: 20811375 First-line Systemic Therapy Trials for Advanced Transitional-cell Carcinoma of the Urothelium: Should We Stop Separating Cisplatin-eligible and -ineligible Patients? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Sep, 2010 | Pubmed ID: 20644092 Second-line Systemic Therapy and Emerging Drugs for Metastatic Transitional-cell Carcinoma of the Urothelium The Lancet. Oncology. Sep, 2010 | Pubmed ID: 20537950 Bladder Cancer: Advances in Treatment and Research Clinical Advances in Hematology & Oncology : H&O. Apr, 2010 | Pubmed ID: 20505645 Suggestions for Regulatory Agency Approval of Second-line Systemic Therapy for Metastatic Transitional Cell Carcinoma Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. May, 2010 | Pubmed ID: 20159797 Target-specific Randomized Discontinuation Trial Design: a Novel Approach in Molecular Therapeutics Investigational New Drugs. Apr, 2010 | Pubmed ID: 19262991 Utility of [18F]2-fluoro-2-deoxyglucose-PET in Sporadic and Tuberous Sclerosis-associated Lymphangioleiomyomatosis Chest. Sep, 2009 | Pubmed ID: 19349386 Patient Selection for Phase II Trials American Journal of Clinical Oncology. Apr, 2009 | Pubmed ID: 19346816 Trial Design for Metastatic Castration-resistant Prostate Cancer Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Jul, 2008 | Pubmed ID: 18640946 Phase I Trial of the Prostate-specific Membrane Antigen-directed Immunoconjugate MLN2704 in Patients with Progressive Metastatic Castration-resistant Prostate Cancer Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. May, 2008 | Pubmed ID: 18362364 Current Optimal Chemotherapy for Advanced Urothelial Cancer Expert Review of Anticancer Therapy. Jan, 2008 | Pubmed ID: 18095883 Nouveaux Agents Du Cancer Urothélial Envahissement Musculaire Et Avancé BJU International. Apr, 2008 | Pubmed ID: 18005203 Germ-cell Tumors The New England Journal of Medicine. Oct, 2007 | Pubmed ID: 17969229 Thérapie Néoadjuvante Suivie D'une Prostatectomie Pour Cancer De La Prostate Cliniquement Localisé Cancer. Dec, 2007 | Pubmed ID: 17941029 Outcomes and Prognosis in Advanced Renal Cell Carcinoma Expert Review of Anticancer Therapy. Jun, 2007 | Pubmed ID: 17555394 Prospective Trial of Ifosfamide, Paclitaxel, and Cisplatin in Patients with Advanced Non-transitional Cell Carcinoma of the Urothelial Tract Urology. Feb, 2007 | Pubmed ID: 17320659 High-dose Bicalutamide After Radiotherapy for Locally Advanced Prostate Cancer: a Standard of Care? Nature Clinical Practice. Urology. Mar, 2007 | Pubmed ID: 17297500 Phase II Trial of Dose-dense Doxorubicin Plus Gemcitabine Followed by Paclitaxel Plus Carboplatin in Patients with Advanced Urothelial Carcinoma and Impaired Renal Function Cancer. Feb, 2007 | Pubmed ID: 17200962 Phase II Trial of Pemetrexed As Second-line Therapy in Patients with Metastatic Urothelial Carcinoma Investigational New Drugs. Jun, 2007 | Pubmed ID: 17146733 Targeting Growth Factor and Antiangiogenic Pathways in Clear-cell Renal Cell Carcinoma: Rationale and Ongoing Trials Clinical Genitourinary Cancer. Dec, 2006 | Pubmed ID: 17239282 Problems with the Randomized Discontinuation Design Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Oct, 2006 | Pubmed ID: 17008711 Impact of Renal Impairment on Eligibility for Adjuvant Cisplatin-based Chemotherapy in Patients with Urothelial Carcinoma of the Bladder Cancer. Aug, 2006 | Pubmed ID: 16773629 Violaceous Exanthem As a Manifestation of Metastatic Prostate Cancer in Skin Urology. Feb, 2006 | Pubmed ID: 16461102 A Retrospective Evaluation of Second-line Chemotherapy Response in Hormone-refractory Prostate Carcinoma: Second Line Taxane-based Therapy After First-line Epothilone-B Analog Ixabepilone (BMS-247550) Therapy Cancer. Jan, 2006 | Pubmed ID: 16329138 The Integration of Chemotherapy and Surgery for Bladder Cancer Journal of the National Comprehensive Cancer Network : JNCCN. Jan, 2005 | Pubmed ID: 19813322 The Role of Taxanes in the Management of Bladder Cancer The Oncologist. Nov-Dec, 2005 | Pubmed ID: 16314289 Prognostic Significance of Baseline Reverse Transcriptase-PCR for Prostate-specific Antigen in Men with Hormone-refractory Prostate Cancer Treated with Chemotherapy Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jul, 2005 | Pubmed ID: 16033836 Bladder Cancer "adjuvant-lite": Tastes Great (works As Well) and Less Filling (less Toxic)? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Aug, 2005 | Pubmed ID: 15939919 Multi-institutional Randomized Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) with or Without Estramustine Phosphate in Patients with Progressive Castrate Metastatic Prostate Cancer Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Mar, 2005 | Pubmed ID: 15735119 Génération de cancer de la prostate des patients Dérivé modèles de xénogreffe de cellules tumorales circulantes Estrelania S. Williams1, Veronica Rodriguez-Bravo3, Uma Chippada-Venkata2, Janis De Ia Iglesia-Vicente1, Yixuan Gong2, Matthew Galsky2, William Oh2, Carlos Cordon-Cardo1, Josep Domingo-Domenech1 1Department of Pathology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 2Department of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 3Molecular Biology Program, Memorial Sloan-Kettering Cancer Center Médecine
Génération de cancer de la prostate des patients Dérivé modèles de xénogreffe de cellules tumorales circulantes Estrelania S. Williams1, Veronica Rodriguez-Bravo3, Uma Chippada-Venkata2, Janis De Ia Iglesia-Vicente1, Yixuan Gong2, Matthew Galsky2, William Oh2, Carlos Cordon-Cardo1, Josep Domingo-Domenech1 1Department of Pathology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 2Department of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 3Molecular Biology Program, Memorial Sloan-Kettering Cancer Center Médecine